Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Humoral Response to TBE Vaccine in Elderly
NCT02318069Phase 3Completed
- Sponsor
- Region Sörmland
- Start
- Jan 2015
- Primary completion
- Feb 2016
- Modality
- Whole Inactivated Vaccines
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of FSME-IMMUN in tick-borne encephalitis (TBE) (5 arms), sponsored by Region Sörmland. Primary endpoint: Serum concentration of neutralising antibodies against TBE one month after an additional dose the following year at 18 months. Started Jan 2015; status: completed.
02
Drugs
FSME-IMMUN
03
Conditions
tick-borne encephalitis (TBE)
Beyond the preview
Go deeper on NCT02318069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02318069.